Traws Pharma, Inc.

Listed Company

TRAWCIK 0001130598NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$2.79M

Net Income

$9.17M

Total Assets

—

Equity

—

Shares Out

15.15M

Op. Cash Flow

$-18.18M

TRAW$0.68−58.26% · past yearDBEQ Basic

Daily closing prices

Business

Traws Pharma is a clinical-stage biopharmaceutical company developing novel antiviral therapies for respiratory viral diseases including influenza and COVID-19, and oncology candidates. The company's lead programs include tivoxavir marboxil (a cap-dependent endonuclease inhibitor for influenza and bird flu), ratutrelvir (a 3CL protease inhibitor for COVID-19), narazaciclib (a multi-targeted kinase inhibitor for solid tumors and hematologic malignancies), and rigosertib (a polo-like kinase inhibitor). Traws operates globally with clinical trials conducted in multiple jurisdictions and licensing partnerships in China, Japan, Korea, Latin America, Canada, Israel, and Australia.

Summary from 10-K filed 2026-04-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	3	226,000	226,000	226,000	226,000
Acquired in-process research and development	—	117	—	—	—
Research and development	12	13	11	—	—
General and administrative	9	12	9	8	9
Total operating expenses	21	143	21	20	17
Loss from operations	−18	−142	−20	−20	−16
Change in fair value of warrant liability /Series A warrant and pre-funded warrant expense	27	−24	—	—	321,000
Other income, net	478,000	289,000	1	663,000	12,000
Net income (loss)	9	−167	−19	—	—
Net income (loss) attributable to common stockholders, basic	7	−55	−19	—	—
Net income (loss) attributable to common stockholders, diluted	7	−55	−19	—	—
Weighted-average shares of common stock outstanding, basic (in shares)	8	2	839,554	21	17
Net income (loss) per share of common stock, basic (in dollars per share)	0.83	−35.21	−22.57	−0.91	−0.96
Weighted-average shares of common stock outstanding, diluted (in shares)	8	2	839,554	21	17
Net income (loss) per share of common stock, diluted (in dollars per share)	0.82	−35.21	−22.57	−0.91	−0.96
Net income (loss) attributable to Series C Preferred stockholders, basic	2	−112	—	—	—
Net income (loss) attributable to Series C Preferred stockholders, diluted	2	−112	—	—	—
Weighted-average shares of Series C Preferred outstanding, basic (in shares)	6,906	7,941	—	—	—
Weighted-average shares of Series C Preferred outstanding, diluted (in shares)	6,906	7,941	—	—	—
Net income (loss) per share of Series C Preferred, basic (in dollars per share)	333.77	−14,085	—	—	—
Net income (loss) per share of Series C Preferred, diluted (in dollars per share)	333.77	−14,085	—	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	4	21	21	39	55
Tax incentive and other receivables	4	2	18,000	29,000	28,000
Prepaid expenses and other assets	365,000	2	2	561,000	332,000
Total current assets	8	25	23	39	55
Property and equipment, net	7,000	10,000	22,000	24,000	38,000
Intangible assets, net	3	—	—	—	—
Other assets	104,000	1,000	1,000	1,000	10,000
Total assets	11	25	23	39	55
Accounts payable	6	8	6	4	3
Accrued expenses and other liabilities	5	3	3	4	3
Deferred revenue	—	226,000	226,000	226,000	226,000
Total current liabilities	11	12	9	8	6
Deferred revenue, non-current	—	3	3	3	3
Warrant liabilities	100,000	42	—	—	—
Total liabilities	11	57	12	11	9
Commitments and contingencies (Note 6)	—	—	—	—	—
Series C Preferred stock, $0.01 par value, 5,000,000 shares authorized, 7,440 shares issued and 6,737 shares outstanding at December 31, 2025 and 7,440 shares issued and 7,398 outstanding at December 31, 2024	—	—	—	—	—
Common stock, $0.01 par value, 250,000,000 shares authorized, 9,067,774 and 3,650,731 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	90,000	36,000	9,000	209,000	209,000
Additional paid in capital	639	618	493	492	491
Accumulated deficit	−640	−649	−483	−464	−445
Accumulated other comprehensive income (loss)	6,000	−42,000	−23,000	−33,000	−14,000
Total stockholders' deficit	−629,000	−32	11	28	46
Total liabilities and stockholders' deficit	11	25	23	39	55

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	9	−167	−19	—	—
Depreciation and amortization	61,000	12,000	16,000	14,000	14,000
Stock-based compensation	728,000	1	1	1	576,000
Receivables	−2	−2	11,000	−1,000	9,000
Prepaid expenses and other current assets	1	−27,000	−1	−229,000	530,000
Accounts payable	−612,000	646,000	2	1	−2
Accrued expenses and other current liabilities	2	−5	−585,000	828,000	−2
Deferred revenue	−3	−226,000	−226,000	−226,000	−226,000
Net cash used in operating activities	−18	−30	−18	−16	−19
Cash paid for acquisition, net of cash acquired	−3	−4	—	—	—
Net cash used in investing activities	−3	−4	−14,000	—	—
Proceeds from sale of common stock pursuant to the ATM	6	—	—	—	55
Payment of offering costs	−2	—	—	—	—
Proceeds from exercised prefunded warrants	26,000	—	—	—	495,000
Net cash provided by financing activities	3	34	—	—	56
Effect of foreign currency translation on cash	48,000	−19,000	10,000	−19,000	−28,000
Net (decrease) increase in cash and cash equivalents	−18	517,000	−18	−16	36
Reclassification of warrant liability upon exercise of prefunded warrants and amended warrant agreements	16	—	—	—	—
Preferred stock issued in connection with the reclassification and conversion of redeemable convertible preferred stock	—	112	—	—	—
Common stock issued in connection with acquisition of Trawsfynydd	—	4	—	—	—
Preferred stock issued in connection with acquisition of Trawsfynydd	—	98	—	—	—
Offering costs included in other assets	104,000	—	—	—	—
Offering costs included in accounts payable	—	2	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Traws Pharma, Inc.'s CIK number?

Traws Pharma, Inc.'s SEC CIK number is 0001130598 (1130598). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Traws Pharma, Inc.'s SEC filings?

All of Traws Pharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Traws Pharma, Inc. last report earnings?

Traws Pharma, Inc. (TRAW) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-061771). This is Traws Pharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Traws Pharma, Inc.'s most recent earnings 8-K?

Traws Pharma, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001104659-26-061771. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Traws Pharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →